Recent Press Releases

Lilly, Zymeworks Announce Expansion of Strategic Licensing and Collaboration Agreement

Broad Bi-Specific Antibody Collaboration Now Includes Targets that Could Lead to New Cancer Immunotherapies

Viamet Announces $60 Million Series D Financing

RESEARCH TRIANGLE PARK, N.C., Oct 21, 2014 (BUSINESS WIRE) -- Viamet Pharmaceuticals Holdings, LLC (Viamet) today announced the closing of a $60 million Series D financing provided by Brandon Point...

Roche invests for the future in its Basel site

Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development Today Roche presented development plans for its Basel site. Over the...

A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment History

- Interim Results from Ongoing Study Demonstrate Human Proof-of-Concept and Underscore the Value of Regulus' microRNA Platform - - Conference Call Today at 8:30 a.m. EDT to Discuss Results - LA...

Johnson & Johnson Announces Major Commitment to Speed Ebola Vaccine Development and Significantly Expand Production

New Brunswick, N.J., (Oct. 22, 2014) – Johnson & Johnson (NYSE: JNJ) today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the...

U.S. Food and Drug Administration accepts filing of new drug application for empagliflozin/metformin fixed-dose combination

RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 21, 2014 -- The U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for empagliflozin plus immediate-release...

RegeneRx Allowed to Proceed with Phase 3 Using RGN-259 Eye Drops for the Treatment of Neurotrophic Keratopathy

ROCKVILLE, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx") today announced that it met with the FDA in September and as a result of the meeting...

Inovio Pharmaceuticals, MedImmune and the University of Pennsylvania Partner to Combat Influenza and Antibiotic Resistant Bacteria

PLYMOUTH MEETING, Pa., Oct. 21, 2014 -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today the Defense Advanced Research Projects Agency (DARPA) has awarded $12.2 million for a collaborative...

Fidelity Biosciences and Atlas Venture Lead $12 Million Series A Funding to Launch Unum Therapeutics, a New Cellular Immunotherapy Company

Unum has built a universal cellular immunotherapy platform based on proprietary antibody-coupled T-cell receptor (ACTR) technology CAMBRIDGE, MA, October 21, 2014 – Unum Therapeutics, a company...

Omeros Provides Update on PDE10 Inhibitor Program

SEATTLE, Oct. 21, 2014 -- Omeros Corporation (OMER) today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and...

Analyst Scanner on Biotech Equities - Amgen, Exelixis, Regeneron Pharma, Lexicon Pharma, and BioMarin Pharma

Editor Note: For more information about this release, please scroll to bottom.

LONDON, October 20, 2014

Cytokinetics Provides Development Program Update for Tirasemtiv

Robust Effects of Tirasemtiv on Slow Vital Capacity Observed in BENEFIT-ALS Support Progression to Phase III Company Believes Effects on Slow Vital Capacity Could Support Registration Path For...

CUBIST PHARMACEUTICALS NAMES ROBERT J. PEREZ CHIEF EXECUTIVE OFFICER

— 10/20/2014 Michael W. Bonney to Become Non-Executive Chair of the Board of Directors Kenneth M. Bate to Become Lead Independent Director Lexington, Mass., October 20, 2014 – Cubist...

Interim Chief Financial Officer James Bowling to Step Down

Interim Chief Financial Officer James Bowling to Step Down DUBLIN, October 20, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that James Bowling, Interim Chief Financial Officer...

Phase II Data in Crohn's Disease for Celgene's Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014

BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that results from a double-blind,...

TesoRx and Aspen Group Conclude Investment and Licensing Agreement

(Menlo Park, CA, United States and Grande Bay, Mauritius) October 20, 2014 – TesoRx Pharma, LLC (http://www.tesorx.com), a specialty pharmaceutical company, announced today that it has licensed...

SELLAS Life Sciences Group Selects PPD As Its Strategic CRO Partner To Advance Zolpidem And WT1 Cancer Vaccine

ZUG, Switzerland and NEW YORK -- SELLAS Life Sciences Group (SELLAS), a Swiss-based development-stage biopharmaceutical company, today announced that it has signed a definitive master service...

PureTech Announces Expansion with Oversubscribed $55M Funding Round

BOSTON, Oct. 20, 2014 -- PureTech, a science and technology development and commercialization company tackling big healthcare problems, announced today the closing of a $55 million growth stage...